Ideaya Biosciences Inc (IDYA) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Ideaya Biosciences Inc   (NASDAQ: IDYA)


Ideaya Biosciences Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Ideaya Biosciences Inc's ROI in the second quarter of 2026?
Ideaya Biosciences Inc recorded a cumulative net loss of $-175 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -16.04%.

Within the Healthcare sector 78 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 1958 to 3120.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 2.07 % -2.32 % 2.47 % 14.93 % 42.72 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 1,227 966 1,051 1,121 986
Return On Investment (TTM) -16.04 % -13.59 % -10.81 % -15.25 % -31.04 %
IDYA's Overall Ranking # 3120 # 1958 # 1271 # 2056 # 2887
Seq. Investment Change TTM 5.84 % -2 % -0.2 % -1.4 % 1.29 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -175 -140 -114 -161 -332

IDYA Company Profile >> Back to IDYA Roi Comparisons >> See Annual IDYA Return On Investment



Return On Investment IDYA's Ranking
Within: No.
Industry # 20
Sector # 79
Overall # 3120

Return On Investment Statistics
High Average Low
-4.91 %
-18.08 %
-33.59 %
(Sep 30 2020)   (Jun 30 2019)



  News about Ideaya Biosciences Inc Return on Investment ROI

IDEAYA Biosciences Advances B7H3/PTK7 Bispecific ADC Development with Biocytogen Collaboration Amidst Financial Chall...

November 11, 2024

In a significant advancement within the biotechnology sector, Biocytogen Pharmaceuticals (Beijing) Co. Ltd. has announced that IDEAYA Biosciences, Inc. has exercised its option for an exclusive worldwide license regarding Biocytogen s promising B7H3/PTK7 bispecific antibody-drug conjugate (BsADC) programme, IDE034. This pivotal decision heralds the potential for IDE034 to become a first-in-class therapeutic aimed at addressing pressing oncological needs.The declaration was made from both Biocytogen s headquarters in Beijing and IDEAYA s base in South San Francisco, California. Biocytogen, listed on the Hong Kong Stock Exchange under the ticker HKEX: 02315, is renowned for its commitment to the discovery of innovative antibody and ADC therapeutics. By transferring the developmental rights for IDE034, which targets the dual mechanisms of B7H3 and PTK7, IDEAYA aims to harness the therapeutic potential that this bispecific entity may provide in the oncology arena.

IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Steer Corporate Strategy and Overcome Financial Challenges.

May 28, 2024

IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business Development
IDEAYA Biosciences, a precision medicine company specializing in oncology, has recently announced the appointment of Daniel A. Simon as the new Chief Business Officer. Simon brings with him extensive experience in the life sciences industry and strategy consulting across various reputable companies.
During his impressive 18-year career, Simon has held key positions at Revolution Medicines, Guardant Health, Onyx Pharmaceuticals, and McKinsey and Company. These roles have equipped him with a deep understanding of the biotech sector and valuable insights into corporate strategy and business development.





Financial Statements
Ideaya Biosciences Inc's II. Quarter Investments $ 1,227 Millions IDYA's Balance sheet
Ideaya Biosciences Inc's II. Quarter Income $ -112 Millions Quarterly IDYA's Income Statement
IDYA's Income by Division See IDYA's Income by Division


IDYA Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 1,023 1,059 621 356 336
Y / Y Investment Growth -3.42 % 70.53 % 74.34 % 5.97 % 29.49 %
Net Income in Millions -114 -274 -113 -59 -50
Y / Y Net Income Growth - - - - -
Annual Return On Investment -11.11 % -25.91 % -18.19 % -16.46 % -14.8 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
IDYA's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for IDYA's Competitors
Subscribers only: Roi for Ideaya Biosciences Inc's Suppliers
Subscribers only: Return On Investment for IDYA's Customers

Other Ratios
IDYA's Roa IDYA's Inventory Turnover Ratio IDYA's Growth Rates IDYA's Dividend Statistics
IDYA's Profitability Ratios IDYA's Asset Turnover Ratio IDYA's Dividend Growth
IDYA's Roe IDYA's Valuation Ratios IDYA's Financial Strength Ratios IDYA's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-08-30T22:00:23+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.